Ranbaxy Laboratories declines on recalling over 64,000 bottles of generic Lipitor in United States

11 Mar 2014 Evaluate

Ranbaxy Laboratories is currently trading at Rs. 362.90, down by 1.60 points or 0.44 % from its previous closing of Rs. 364.50 on the BSE.

The scrip opened at Rs. 364.30 and has touched a high and low of Rs. 370.95 and Rs. 362.00 respectively. So far 284505 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 490.15 on 06-Jan-2014 and a 52 week low of Rs. 253.95 on 02-Aug-2013.

Last one week high and low of the scrip stood at Rs. 375.00 and Rs. 353.25 respectively. The current market cap of the company is Rs. 15501.84 crore.

The promoters holding in the company stood at 63.41 % while Institutions and Non-Institutions held 19.55 % and 15.38 % respectively.

Ranbaxy Laboratories, India’s largest pharmaceutical company has recalled some batches of its generic version of cholesterol-lowering Lipitor drug in the United States after a dosage mix-up was detected. The company voluntarily recalled 64,626 bottles containing atorvastatin calcium tablets, the generic version of Pfizer Inc's cholesterol fighter Lipitor, after a pharmacist found a 20-milligram tablet in a sealed bottle marked for 10-milligram tablets.

Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1486.55
Dr. Reddys Lab 5860.25
Cipla 1482.55
Zydus Lifesciences 1072.35
Lupin 1613.65
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.